WeVote
Log In

Bill

Bill

HSB 209

A bill for an act relating to a review of anti-obesity medications by the department of health and human services for purposes of the medical assistance program.

2025-2026 Regular Session

DHHS will review anti-obesity medications for Iowa Medicaid, evaluating effectiveness, health impacts, and cost savings to propose eligibility criteria and report findings.

Committee report approving bill, renumbered as HF 701.
#healthandhumanservicesdepartment #medicalassistance #prescriptiondrugs
0
WeVote Research Nonpartisan
Bill Summary · HSB 209

Summary: HSB 209 (renumbered as HF 701) — Review of Anti-Obesity Medications for Medicaid

What the bill aims to do

  • Purpose: Direct the Department of Health and Human Services (DHHS) to review anti-obesity medications for the Medicaid program (chapter 249A) to assess their overall value and feasibility within the program.
  • Core focus: Evaluate effectiveness, impact on obesity-related comorbidities, potential cost savings (including deferred medical procedures and reduced use of other medications related to comorbidity), and to consider eligibility criteria and any other relevant criteria DHHS deems appropriate.
  • Deliverable: DHHS must submit a report to the General Assembly detailing findings and proposed eligibility requirements for Medicaid coverage of anti-obesity medications.

Key Provisions

  • Review scope for Medicaid (chapter 249A): DHHS shall assess
    • Effectiveness of anti-obesity medications in the Medicaid population
    • Impact on comorbid conditions associated with obesity
    • Potential cost savings, including
    • Deferred or avoided medical procedures
    • Reduced medications related to obesity-related comorbidity
    • Eligibility requirements and any other criteria DHHS considers relevant
  • Report to the General Assembly: A comprehensive report outlining findings and proposed eligibility criteria for anti-obesity medications within Medicaid

Who/What is Affected

  • Primary program: Iowa Medicaid (Medical Assistance) under chapter 249A
  • Affected parties:
    • Medicaid enrollees who might use anti-obesity medications
    • Healthcare providers prescribing anti-obesity medications to Medicaid beneficiaries
    • DHHS, which would conduct the review and publish the report
  • Implications for policy: The report could inform future Medicaid coverage decisions and eligibility standards for anti-obesity medications

Implementation Timeline and Procedural Points

  • Introduced: February 19, 2025
  • Subcommittee action: February 25, 2025 (subcommittee recommended passage)
  • Subcommittee meeting: February 25, 2025 (noted in actions)
  • Committee action: February 26–28, 2025
    • Subcommittee recommended passage
    • Committee reported approving the bill
  • Renumbering: The bill was renumbered as HF 701 during committee action
  • Final report deadline: December 1, 2025
    • DHHS must submit the report to the General Assembly by this date, including findings and proposed eligibility requirements

Status and Next Steps

  • Status: Committee report approving the bill; renumbered as HF 701
  • Next steps: If advanced, HF 701 would proceed through the legislative process with the DHHS review and final eligibility framework potentially informing future Medicaid policy decisions for anti-obesity medications

Observations

  • This is a study-and-reporting measure rather than an immediate funding or mandate change.
  • The bill emphasizes data on effectiveness, health outcomes, and potential cost offsets to justify or guide eligibility criteria for Medicaid coverage of anti-obesity medications.
  • The December 1, 2025 reporting deadline frames subsequent legislative consideration based on DHHS findings.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.